An investigator-initiated clinical research on the ability of an electroencephalogram analysis program to differentiate between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD)

Not Applicable

• Conditions: dementia with Lewy bodies (DLB) , Alzheimer' s disease (AD)

• Registration Number: JPRN-UMIN000035926
• Lead Sponsor: Department of Behavioral Neurology and Neuropsychiatry, Osaka University United Graduate School of Child Development

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-03-11
• Study Completion: 2019-12-04
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

1)Subject or responsible caregiver is unable or unwilling to give informed consent. 2)Presence of local or diffuse vascular lesions on MRI or CT, where this is thought to be the cause of, or contribute to the severity of the subject's dementia. 3)Suffering from a significant neurologic disease other than probable DLB or AD. 4)Systemic diseases possibly contributing to the severity of dementia. 5)History of alcohol or drug abuse or dependence within the past 2 years. 6)History of schizophrenia. 7)Any significant systemic illness or unstable medical condition that may affect EEG. 8)Use of specific medications: a)Centrally active beta-blockers (propranolol), methyldopa and clonidine within 4 weeks prior to screening, narcotics. b)Use of anti-Parkinsonism medications other than levodopacarbidopa, or levodopa benserazide within 4 weeks prior to screening. c)Neuroleptics or narcotic analgesics within 4 weeks prior to screening d)Long acting benzodiazepines or barbiturates within 4 weeks prior to screening e)Use of short-acting anxiolytics or sedative hypnotics more than 2 times per week within 4 weeks prior to screening. 9)Patients currently using memantine. Cholinesterase inhibitors are permitted if doses are stable for 4 weeks prior to screening. 10)Use of any investigational drugs within 30 days or 5 half lives prior to screening. 11)Subjects who, in the Principal Investigator's opinion, are unlikely to comply with the EEG recording procedure.

Study & Design

• Study Type: Interventional
• Study Design: Not specified